Bullous Pemphigoid-like Rash Revealing Hypereosinophilic Syndrome

Overview

Journal BMJ Case Rep

Specialty General Medicine

Date 2021 Jun 9

PMID 34103306

Citations 3

Authors

Mehdi Khallaayoune

Sanae Sialiti

Mariame Meziane

Karima Senouci

Affiliations

Soon will be listed here.

Abstract

Hypereosinophilic syndrome (HES) is a rare haematologic disorder characterised by unexplained, persistent eosinophilia with organ involvement. We report the case of a 74-year-old patient who presented with a pemphigoid-like bullous rash as the only manifestation of an HES. This report highlights the importance of the dermatological manifestations of this potentially life-threating condition that may initially present as a skin-limited disease. Bullous pemphigoid (BP) is a very common autoimmune blistering dermatosis that may share common clinical and histological features or associate with an HES. HES should be considered when patients diagnosed with BP demonstrate atypical course under corticosteroids and/or recalcitrant blood eosinophilia.

Citing Articles

Retrospective Analysis of 397 Dermatoses Inpatients Associated with Blood Eosinophilia.

Zhao Y, Tian J, Gao C, Liu L, Pan L, Song Z Clin Cosmet Investig Dermatol. 2023; 16:3455-3463.

PMID: 38077918 PMC: 10700038. DOI: 10.2147/CCID.S429183.

Recalcitrant course of bullous pemphigoid indicating coexisting hypereosinophilic syndrome: A case report and literature review.

Ganji R, Diab R, Mousavi F, Abdollahimajd F Clin Case Rep. 2023; 11(6):e7384.

PMID: 37323291 PMC: 10264926. DOI: 10.1002/ccr3.7384.

Acute Liver Failure Due to Hypereosinophilic Syndrome Accompanied by Duodenal Perforation.

Tange S, Uchino K, Kakiwaki H, Suzuki H, Yamamoto S, Ito Y Intern Med. 2021; 61(10):1525-1529.

PMID: 34670898 PMC: 9177379. DOI: 10.2169/internalmedicine.8283-21.

References

Belgnaoui F, Idrissi M, Benyoussef K, Loudiye T, Bella A, Senouci K . [Idiopathic hypereosinophilic syndrome and bullous pemphigoid]. Ann Dermatol Venereol. 2003; 129(11):1291-4. View

Curto-Barredo L, Segura S, Ishii N, Hashimoto T, Mascaro Jr J, Espinet B . Pemphigus-like hypereosinophilic syndrome with FIP1L1-PDGFRA fusion gene: A challenging and uncommon clinical presentation. J Dermatol. 2019; 46(6):531-534. DOI: 10.1111/1346-8138.14888. View

Leiferman K, Gleich G, Peters M . Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007; 27(3):415-41. DOI: 10.1016/j.iac.2007.07.009. View

Roufosse F, Kahn J, Gleich G, Schwartz L, Singh A, Rosenwasser L . Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2012; 131(2):461-7.e1-5. PMC: 3558744. DOI: 10.1016/j.jaci.2012.07.055. View

Hofmann S, Technau K, Muller A, Lubbert M, Bruckner-Tuderman L . Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib. J Am Acad Dermatol. 2006; 56(5 Suppl):S68-72. DOI: 10.1016/j.jaad.2006.02.059. View

Alfaham M, Ferguson S, Sihra B, Davies J . The idiopathic hypereosinophilic syndrome. Arch Dis Child. 1987; 62(6):601-13. PMC: 1778425. DOI: 10.1136/adc.62.6.601. View

Podjasek J, Butterfield J . Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature. Leuk Res. 2013; 37(4):392-5. DOI: 10.1016/j.leukres.2012.12.016. View

Kuang F, Klion A . Biologic Agents for the Treatment of Hypereosinophilic Syndromes. J Allergy Clin Immunol Pract. 2017; 5(6):1502-1509. PMC: 5718167. DOI: 10.1016/j.jaip.2017.08.001. View

Preda V, Henderson C, Woods J . Isolated symptomatic cutaneous disease in hypereosinophilic syndrome. Australas J Dermatol. 2010; 51(1):60-5. DOI: 10.1111/j.1440-0960.2009.00610.x. View

10.

Plotz S, Huttig B, Aigner B, Merkel C, Brockow K, Akdis C . Clinical overview of cutaneous features in hypereosinophilic syndrome. Curr Allergy Asthma Rep. 2012; 12(2):85-98. DOI: 10.1007/s11882-012-0241-z. View

11.

Joly P, Roujeau J, Benichou J, Picard C, Dreno B, Delaporte E . A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002; 346(5):321-7. DOI: 10.1056/NEJMoa011592. View

12.

Kemmler N, Peitsch W, Glorer E, Goerdt S . [Hypereosinophilic dermatitis. An overlooked diagnosis?]. Hautarzt. 2005; 56(11):1060-7. DOI: 10.1007/s00105-004-0851-z. View

13.

Weigand D . Effect of anatomic region on immunofluorescence diagnosis of bullous pemphigoid. J Am Acad Dermatol. 1985; 12(2 Pt 1):274-8. DOI: 10.1016/s0190-9622(85)80035-9. View

14.

Iwakura R, Oiso N, Tateishi C, Suzuki M, Uchida S, Yanagihara S . Pemphigus foliaceus progressing to bullous pemphigoid. J Dermatol. 2019; 46(11):e424-e426. DOI: 10.1111/1346-8138.15021. View

15.

Simon H, Rothenberg M, Bochner B, Weller P, Wardlaw A, Wechsler M . Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol. 2010; 126(1):45-9. PMC: 3400024. DOI: 10.1016/j.jaci.2010.03.042. View

16.

Offidani A, Bernardini M, Simonetti O, Simoncini C, Giangiacomi M, Bossi G . Hypereosinophilic dermatosis: skin lesions as the only manifestation of the idiopathic hypereosinophilic syndrome?. Br J Dermatol. 2000; 143(3):675-7. DOI: 10.1111/j.1365-2133.2000.03750.x. View

17.

Gotlib J . World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. Am J Hematol. 2015; 90(11):1077-89. DOI: 10.1002/ajh.24196. View

18.

Fudge J, Crawford R . Bullous Pemphigoid: A 10-Year Study of Discordant Results on Direct Immunofluorescence. J Cutan Med Surg. 2018; 22(5):472-475. DOI: 10.1177/1203475418773359. View

19.

Butterfield J . Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol. 2005; 114(1):26-40. DOI: 10.1159/000085560. View

20.

Valent P, Klion A, Horny H, Roufosse F, Gotlib J, Weller P . Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012; 130(3):607-612.e9. PMC: 4091810. DOI: 10.1016/j.jaci.2012.02.019. View